Treatment for COWS Score Greater Than 24
For severe opioid withdrawal (COWS >24), immediately administer buprenorphine 4-8 mg sublingually and reassess after 30-60 minutes, targeting a total dose of 16 mg within the first day to adequately control symptoms. 1
Initial Management Algorithm
A COWS score >24 indicates severe opioid withdrawal requiring urgent pharmacological intervention. The evidence-based approach prioritizes buprenorphine as first-line therapy:
Immediate Dosing Strategy
- Initial dose: Administer 4-8 mg buprenorphine sublingually based on withdrawal severity 1
- Reassessment: Evaluate patient and repeat COWS scoring after 30-60 minutes 1
- Target dose: Aim for 16 mg total buprenorphine on Day 1 for most patients with severe withdrawal 1
- Additional dosing: Continue titrating based on COWS scores until symptoms are adequately controlled
Critical Pre-Treatment Verification
Before administering buprenorphine, confirm adequate time since last opioid use to avoid precipitated withdrawal 1:
- Short-acting opioids (heroin, morphine IR): >12 hours
- Extended-release formulations (OxyContin): >24 hours
- Methadone maintenance patients: >72 hours (consider methadone instead) 1
Evidence Supporting Buprenorphine as First-Line
The 2020 Annals of Emergency Medicine clinical policy guideline establishes buprenorphine as superior to alternatives based on Cochrane review evidence. Patients receiving buprenorphine for withdrawal had less severe signs and symptoms, fewer adverse effects, and were more likely to stay in treatment longer compared to clonidine or lofexidine 1. Buprenorphine demonstrated similar effectiveness to tapered methadone but with more practical ED/acute care application 1.
Alternative and Adjunctive Therapies
If Buprenorphine is Contraindicated or Unavailable
Methadone can be administered for up to 72 hours without participation in an opioid treatment program 1. However, its long duration of action (hours to days) and potential interference with ongoing treatment programs make it less commonly used in acute settings 1.
Symptomatic Management (Adjunctive)
For severe withdrawal, combine opioid agonist therapy with symptom-directed treatments 1:
- α2-agonists: Clonidine or lofexidine (if not hypotensive)
- Antiemetics: Promethazine for nausea/vomiting
- Benzodiazepines: For anxiety, muscle cramps, and catecholamine release
- Antidiarrheals: Loperamide for diarrhea
Prescribing Considerations
For X-Waivered Providers
Prescribe buprenorphine/naloxone 16 mg sublingual daily for 3-7 days or until follow-up appointment 1
For Non-X-Waivered Providers
You may administer (but not prescribe) buprenorphine in the ED/hospital with these restrictions 1:
- Maximum one day's medication at a time
- Treatment cannot exceed 72 hours total
- Must arrange referral for ongoing treatment
Critical Pitfalls to Avoid
Precipitated withdrawal: The most serious complication occurs when buprenorphine is given too soon after full opioid agonist use. The partial agonist properties of buprenorphine can displace full agonists from receptors, worsening withdrawal dramatically. Always verify adequate time since last use.
Underdosing: With COWS >24, inadequate buprenorphine dosing (e.g., only 2-4 mg total) will fail to control severe symptoms. The guideline explicitly recommends targeting 16 mg total for most patients 1.
Methadone patients: Those on methadone maintenance require >72 hours since last dose before buprenorphine, or consider continuing methadone instead 1.
Xylazine co-exposure: Emerging evidence suggests xylazine-adulterated opioids may complicate withdrawal presentation, though standard opioid withdrawal treatment remains appropriate 2.
Discharge Planning and Continuation
Maximize the total buprenorphine dose administered before discharge to ensure adequate symptom control and treatment engagement 1. Essential discharge components include:
- Overdose prevention education and naloxone kit
- Linkage to medication-assisted treatment (MAT) program
- Hepatitis C and HIV screening
- Reproductive health counseling 1
The evidence demonstrates that ED-initiated buprenorphine with outpatient continuation shows better short-term improvement in treatment engagement and reduced illicit opioid use compared to referral alone 1.